

## Product datasheet for **TL300690V**

### UBE2V1 Human shRNA Lentiviral Particle (Locus ID 7335)

#### Product data:

|               |   |
|---------------|---|
| Product Type: | shRNA Lentiviral Particles  |
| Product Name: | UBE2V1 Human shRNA Lentiviral Particle (Locus ID 7335)  |
| Locus ID:     | 7335  |
| Synonyms:     | CIR1; CROC-1; CROC1; UBE2V; UEV-1; UEV1; UEV1A  |
| Vector:       | pGFP-C-shLenti (TR30023)  |
| Format:       | Lentiviral particles  |
| Components:   | UBE2V1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.  |
| RefSeq:       | <a href="#">NM_001032288</a> , <a href="#">NM_001257393</a> , <a href="#">NM_001257394</a> , <a href="#">NM_001257395</a> , <a href="#">NM_001257396</a> , <a href="#">NM_001257397</a> , <a href="#">NM_001257398</a> , <a href="#">NM_001257399</a> , <a href="#">NM_001282575</a> , <a href="#">NM_001282576</a> , <a href="#">NM_001282577</a> , <a href="#">NM_001282578</a> , <a href="#">NM_001282579</a> , <a href="#">NM_001282580</a> , <a href="#">NM_021988</a> , <a href="#">NM_022442</a> , <a href="#">NM_199144</a> , <a href="#">NR_047553</a> , <a href="#">NR_047554</a> , <a href="#">NR_047555</a> , <a href="#">NR_047556</a> , <a href="#">NR_104218</a> , <a href="#">NM_001032288.2</a> , <a href="#">NM_021988.1</a> , <a href="#">NM_021988.2</a> , <a href="#">NM_021988.3</a> , <a href="#">NM_021988.4</a> , <a href="#">NM_021988.5</a> , <a href="#">NM_022442.1</a> , <a href="#">NM_022442.2</a> , <a href="#">NM_022442.3</a> , <a href="#">NM_022442.4</a> , <a href="#">NM_022442.5</a> , <a href="#">NM_199144.1</a> , <a href="#">NM_199144.2</a> , <a href="#">NM_001257394.1</a> , <a href="#">NM_001257396.1</a> , <a href="#">NM_001257393.1</a> , <a href="#">NM_001282580.1</a> , <a href="#">NM_001282575.1</a> , <a href="#">NM_001282575.2</a> , <a href="#">NM_001282577.1</a> , <a href="#">NM_001282577.2</a> , <a href="#">NM_001282578.1</a> , <a href="#">NM_001282578.2</a> , <a href="#">NM_001257397.1</a> , <a href="#">NM_001257398.1</a> , <a href="#">NM_001257399.1</a> , <a href="#">NM_001282576.1</a> , <a href="#">NM_001282579.1</a> , <a href="#">NM_001257395.1</a> , <a href="#">BC000468</a> , <a href="#">NM_001257393.2</a> , <a href="#">BC005215</a> , <a href="#">BC008944</a> , <a href="#">NM_001257396.2</a> , <a href="#">NM_001282575.3</a> , <a href="#">NM_001282578.3</a> , <a href="#">NM_022442.6</a> , <a href="#">NM_021988.6</a> , <a href="#">NM_001032288.3</a> , <a href="#">NM_199144.3</a> , <a href="#">NM_001257394.2</a> , <a href="#">NM_001257397.2</a> , <a href="#">NM_001257395.2</a> , <a href="#">NM_001282577.3</a> , <a href="#">NM_001257399.2</a> |
| UniProt ID:   | <a href="#">Q13404</a>  |



[View online »](#)

- Summary:** Ubiquitin-conjugating E2 enzyme variant proteins constitute a distinct subfamily within the E2 protein family. They have sequence similarity to other ubiquitin-conjugating enzymes but lack the conserved cysteine residue that is critical for the catalytic activity of E2s. The protein encoded by this gene is located in the nucleus and can cause transcriptional activation of the human FOS proto-oncogene. It is thought to be involved in the control of differentiation by altering cell cycle behavior. Alternatively spliced transcript variants encoding multiple isoforms have been described for this gene, and multiple pseudogenes of this gene have been identified. Co-transcription of this gene and the neighboring upstream gene generates a rare transcript (Kua-UEV), which encodes a fusion protein comprised of sequence sharing identity with each individual gene product. [provided by RefSeq, Apr 2012]
- shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact [techsupport@origene.com](mailto:techsupport@origene.com). If you need a special design or shRNA sequence, please utilize our [custom shRNA service](#).
- Performance Guaranteed:** OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
- For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).